Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 13,749 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: CVD - Cardiovascular Disease
Interventions: Education, Providing and Engaging Social Support and Assistance with Health System Navigation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Brain Injuries
Interventions: MRI Scans; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 0 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 18
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 15 more

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions: Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX; Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Testosterone enanthate, Megestrol acetate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Carcinoma of Unknown Primary
Interventions: radiation therapy; Radiation
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 237
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 3,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 208
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: Colitis, Ulcerative
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Anaheim, California • Newport Beach, California • San Diego, California + 28 more

Conditions: Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions: LUCEMYRA (lofexidine) tablets; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: Aventis U-400 Insulin; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Normal Pressure Hydrocephalus (INPH)
Interventions: programmable CSF shunt valve; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Albuquerque, New Mexico • Cleveland, Ohio + 1 more

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
Interventions: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 9 Months
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more

Conditions: Multiple Myeloma
Interventions: Teclistamab, Lenalidomide; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 39
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Bipolar Disorder
Interventions: Riluzole, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more

Conditions: Alzheimer's Disease
Interventions: Posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: ROHHAD Syndrome
Interventions: Cyclophosphamide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Months to 22 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Temporomandibular Joint Disorder
Interventions: Cognitive Therapy for Catastrophizing, Behavioral Therapy for Sleep Continuity Disturbance; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: SIBO, Small Bowel Bacterial Overgrowth Syndrome
Interventions: Hydrogen content recording; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Symptomatic Cervical Disc Disease
Interventions: prodisc C SK and/or Vivo, Mobi-C Cervical Disc; Device
Lead sponsor: Centinel Spine; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 30
States / cities: Flagstaff, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Obstructive Sleep Apnea
Interventions: Trans Nasal Insufflation (TNI) [nasal canula]; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Community Health Worker-Led Intervention to Increase Cardiac Rehabilitation Participation

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

MRI Markers of Outcome After Severe Pediatric TBI

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Medtronic MiniMed Implantable Insulin Pump

A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Biobehavioral Pain Management in TMD

Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)

2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C

Trans Nasal Insufflation for the Treatment of Snoring